Načítá se...
Discovery and characterization of dual inhibitors of MDM2 and NFAT1 for pancreatic cancer therapy
Overexpression and activation of the MDM2 or NFAT1 oncogenes frequently occur in pancreatic cancer. Most MDM2 inhibitors under development target MDM2-p53 binding and have little or no effect on cancers without functional p53, including pancreatic cancer. Some available compounds indirectly inhibit...
Uloženo v:
| Vydáno v: | Cancer Res |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6435280/ https://ncbi.nlm.nih.gov/pubmed/30217928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-3939 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|